-
04:59:45 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

SQZ Stock News

06/21/22 6:45 AM
NYSE : SQZ
clinical triallow float
SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented Tolerizing Antigen Carrier nonclinical results at the 2022 Federation of Clinical Immunology Sciences annual meeting. “We’ ve now shown in different preclinical models of autoimmune disease that SQZ ® TACs have the...
RHEA-AI
neutral
06/16/22 6:45 AM
NYSE : SQZ
low float
SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs
SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, presented preclinical regenerative medicine data showing that the company’ s proprietary Cell Squeeze ® technology can effectively generate dopaminergic neurons from human-induced pluripotent stem cells through the single-step...
RHEA-AI
neutral
05/31/22 4:45 PM
NYSE : SQZ
managementlow float
SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer. Marshelle has tremendous experience in cell-based therapeutic development and will provide complementary expertise as we seek to rapidly advance our...
RHEA-AI
very positive
05/18/22 6:45 AM
NYSE : SQZ
low float
SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
SQZ Biotechnologies announced today that the company’ s first generation, integrated point-of-care cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specifications relative to current clean room-based processes used in clinical development. Data was presented today at the 2022...
RHEA-AI
positive
05/10/22 4:50 PM
NYSE : SQZ
earningslow float
SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported first quarter 2022 financial results and recent portfolio updates. “Our year is off to an exciting start with the FDA IND clearance to initiate clinical trials of our eAPCs– our multifunctional mRNA-based investigational cell...
RHEA-AI
very positive
05/05/22 4:45 PM
NYSE : SQZ
conferenceslow float
SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the company will host a live R&D investor event with optional virtual participation on Thursday, May 19, 2022, from 4:05- 5:30 p.m. ET. Robert S. Langer, Sc.D., Scientific Advisory Board Member and Founder of SQZ Biotechnologies,...
RHEA-AI
neutral
05/05/22 6:45 AM
NYSE : SQZ
clinical triallow float
SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research
SQZ Biotechnologies announced today that the company will present data from the first non-clinical studies of its point-of-care manufacturing system at the 2022 American Society for Gene and Cell Therapy Annual Meeting on May 18. SQZ Biotechnologies CEO and Founder Armon Sharei, PhD holds examples of manufacturing and research (R) Cell Squeeze ® chips.
RHEA-AI
positive
04/27/22 4:45 PM
NYSE : SQZ
low float
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation for the company’ s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors. “We are thrilled to receive...
RHEA-AI
very positive